Kornimate/medical-research-clean huggingface dataset:
cross-sectional study of oral health in patients after parotid-sparing radiation therapy for head and neck cancer

Conditions: Head and Neck Cancer

Summary: the investigators are conducting research about oral health and saliva to find out more about the impact of radiation therapy on the oral health of patients. in order to better understand the role of saliva in maintaining oral health in these patients, the investigators will be collecting, storing, and analyzing the quality of saliva, including the protein content, collected from patients following radiation therapy as well as saliva collected from normal healthy adults.

radiation-induced xerostomia is the most common long term complication of head and neck radiation, is usually permanent and is the most frequent reason for reduced quality of life in these patients. the loss of antimicrobial, buffering, cleansing and remineralizing effects of saliva markedly increases the risk for dental caries. extractions of diseased teeth located in irradiated bone and dental infection involving the bone can trigger osteoradionecrosis (orn), another serious complication of high dose radiation of the jaws. therefore, current dental treatment guidelines recommend the extraction of diseased teeth and any teeth that might require extraction in the future, before radiation therapy. (nci, 1990; rankin et al, 2003; nidcr, 2005) as a result, patients with head and neck cancer often have many or all teeth extracted, especially those patients who are judged unlikely to comply with lifelong, daily topical fluoride, oral hygiene practices and frequent professional dental care. (bruins et al, 1999)

Eligibility criteria:
inclusion criteria: * all subjects who have been enrolled in a parotid-sparing imrt protocol for head and neck cancer at university of michigan. * at least 6 months has elapsed since the completion of rt, at the time of assessment for this study. * all subjects must sign a university of michigan health system- irb approved informed consent. * documented karnofsky performance status \> 60 * these subjects will all have american joint committee on cancer (ajcc) stage iii or stage iv disease. (green et al, 2001) (appendix 2); non-metastatic, curable disease exclusion criteria: * history of surgical removal of major salivary gland(s). * patients edentulous prior to radiation therapy. * pregnancy or lactation * patients residing in prison. * age\< 18 years.
two anger management programs for teens.

Conditions: Anger; Hostility; Aggression

Summary: the general aim of the proposed pilot study is to evaluate the the efficacy of mind-body bridging (mbb) for anger management compared with the real deal anger management program, in helping adolescents control or reduce their anger.

in this pilot randomized-controlled study, we evaluate the effects of mbb as compared with an established anger management program (real deal), in helping youth prone to anger develop tools to effectively reduce and control their anger, and potentially reduce other negative emotions and feelings that might be associated with their anger.

Eligibility criteria:
inclusion criteria: * english-speaking * self-, or allo-referred (parents, peers, court-ordered, school, etc.), based on their propensity for displaying various disruptive, externalizing behaviors, including, anger, hostility, oppositional behavior, and temper outbursts, and as such identified by youth services (ys) as a suitable candidate to attend a ys anger management program. exclusion criteria: * none

Keywords: mindfulness cognitive behavior therapy awareness anger aggression
is isokinetic testing an indicator of total knee arthroplasty

Conditions: Knee Osteoarthritis

Summary: in this study, investigators analyzed whether the isokinetic knee muscle strength of patients undergoing unilateral total knee arthroplasty (tka) is a predictor for surgery. patients and methods: in total, 29 unilateral tka candidates (58 knees; mean age = 66.69 ± 7.42 years; mean symptom duration = 10 ± 5.40 years) were enrolled. the knees of patients with bilateral advanced knee osteoarthritis (stage 3 or 4), according to the kellgren-lawrence (k-l scale), that were scheduled for unilateral tka were divided into surgical and non-surgical groups. an isokinetic testing system was used to assess knee flexor and extensor muscle strength (peak torque) at angular velocities of 60°/s and 180°/s (five cycles per velocity). the radiological (x-ray-based k-l scale and magnetic resonance imaging (mri)-based quadriceps angle) and clinical findings (isokinetic test and visual analog scale pain scores) in both groups were compared. the isokinetic test results correlated with the radiological findings of the surgery group.


Eligibility criteria:
inclusion criteria: * diagnosis of advanced (kellgren-lawrence stage 3 or 4) bilateral knee osteoarthritis (oa). * unilateral total knee replacement surgery recommended by orthopedics according to pain status exclusion criteria: * neurological diseases that could affect knee muscle strength * rheumatological diseases * diagnosis of osteoarthritis below 3 according to kellgren-lawrence classification

Keywords: arthroplasty diagnostic x-ray knee muscle strength dynamometer visual analog scale
mk0457 (an aurora kinase inhibitor) study in patients with advanced colorectal cancer and other advanced solid tumors (0457-001)

Conditions: Colorectal Cancer; Advanced Solid Tumors

Summary: study with an investigational drug in patients with recurrent or non-responsive colorectal cancer or other advanced solid tumors. this is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (full information is available to trial participants).


Eligibility criteria:
inclusion criteria: * in part i, patients who are at least 18 years of age with advanced solid tumors and colorectal cancer will be eligible for the first part of this study. patient must have recovered from and be at least 3 weeks from previous cancer treatment. * in part ii, only patients with colorectal cancer will be eligible to participate. the patients may have received up to 3 prior treatments for their colorectal cancer. patients must have recovered from and be at least 3 weeks from previous therapy. exclusion criteria: * patients who have had treatment with any investigational drug within the past 30 days. * patients who have certain types of blood cancers such as leukemia or lymphoma. * patients who have uncontrolled congestive heart failure (chf), chest pain, or heart attack within the past 3 months. * patient is pregnant or nursing.
pain reduction for limb injuries in pediatric emergency departments: intranasal fentanyl or intranasal ketamine vs oral morphine

Conditions: Limb Injury

Summary: the purpose of this study is to determine if in fentanyl (1.5 µg/kg) or in ketamine (1 mg/kg) is more effective at 30 minutes than oral morphine (0.5 mg/kg) in reduction of moderate and severe pain associated with limb injuries in patients 2-17 years of age presenting to the ed.

in children with moderate to severe pain due to musculoskeletal injuries, the first-line analgesic therapy in pediatric emergency departments (ed) is oral or intravenous morphine. due to the delay or discomfort associated with establishing iv access, oral forms are preferred in french ed. unfortunately, oral morphine alone or with ibuprofen or paracetamol, none regimen is optimal for relieving pain in children with traumatic limb injuries. however, the use of intranasal course is a safe route that can provide rapid and almost immediate analgesia. intranasal administration is easy, non-invasive and usually well tolerated by children. in the last years, drugs with analgesic and sedative properties is increasing, particularly on fentanyl, ketamine, which can be also administered by the in route. there are currently no studies, neither published nor ongoing, which compare in fentanyl or in ketamine to a standard oral morphine for children with acute moderate to severe pain with limb injuries presenting to the ed. the main hypothesis is that the efficacy of the analgesia 30 minutes after the administration will be higher with in fentanyl or with in ketamine, when compared to oral morphine.

Eligibility criteria:
inclusion criteria: * child aged 2 years to 17 years and 11 months * with 10 kg ≤ weight ≤ 100 kg * presenting to ed with a traumatic pain and suspected fracture(s) based on an acute deformity and experiencing pain and/or functional impotence in the injured limb(s) * within the first 12 hours after the injury * vas pain score at ed arrival ≥ 60/100 (if child ≥ 7 years) or evendol pain score at ed arrival ≥ 7/15 (if child \< 7 years) * affiliated to health insurance * at least one signed parental informed consent exclusion criteria: * received narcotic pain medication prior to arrival * contraindication to morphine, mentioned in smpc * hypersensitivity to ketamine or fentanyl or to excipients (sodium chloride, sodium hydroxide), or to other opioids. * contraindication to fentanyl or ketamine, mentioned in smpc * gcs \<15 * evidence of significant femur, head, chest, abdominal, or spine injury * open fracture * nasal trauma or complete nasal obstruction * active epistaxis * nasal or sinus surgery within 6 months before inclusion * history of high blood pressure, known coronary artery disease, congestive heart failure, acute glaucoma, increased intracranial pressure, major psychiatric disorder, hepatocellular insufficiency * active or history of psychiatric disorder * known pregnancy or suspicion of being pregnant * breastfeeding * non-french speaking parent and / or child. * participation to another interventional clinical research

Keywords: fentanyl ketamin limb injury pain children
results of cold stored allografts in vascular access

Conditions: End Stage Renal Failure on Dialysis; Hemodialysis Access Failure

Summary: vascular access creation in patients with renal failure requiring long-term hemodialysis can be a challenge when there is no more autologous material or in case of infection, in a population undergoing long term dialysis with a longer life-expectancy. many types of grafts have been used, with its advantages and drawbacks, such as prosthetic grafts (ptfe). over the past decade, surgeons have used cold stored venous allografts as a biological conduit for hemodialysis, with the idea of avoiding most of major complications including a lower incidence of infection and steal syndrome, with patencies at least equivalent to ptfe. there is only a few data in the litterature, but many surgical teams use it when there is no autologous material or in case of infection. the aim of the study is to give the primary patency of vascular access with this technique, and to assess its long term outcomes.


Eligibility criteria:
inclusion criteria: * end stage renal failure patient requiring hemodialysis * with the placement of a venous allograft for a hemodialysis approach * who underwent a surgery between january 1, 2014 and december 31, 2018 in a vascular surgery department participating in our study exclusion criteria: * patient \<18 years old, or under guardianship / curatorship * patient objecting to the use of his personal data in the context of research

Keywords: hemodialysis vascular access homologous vein allogenous vein graft cold stored venous allograft saphenous vein haemodialysis biological graft patency primary patency secondary patency complication
effect of vitamin d diffiency on oral mucosa in patients recieving methotrexate chemotherapy

Conditions: Acute Lymphoblastic Leukemia

Summary: it's a prospective study aiming to improve quality of life of patients with acute lymphoblastic leukemia suffering from oral mucositis, receiving courses of methotrexate chemotherapy , by measuring vitamin d in those patients before induction therapy and the change in its level during treatment, that associated with methotrexate-induced oral mucositis, taking in consideration serum level of methotrexate, so we may have assiotiation between vitamin d difficiency and oral mucositis . at the end we can have preventive interventions to protect against this harmful side effect.

treatment outcome of acute lymphoblastic leukemia (all) is improved recently and the 5-year survival rates reached 90% in developed countries . so more research currently focuses on strategies to decrease toxic adverse effects of methotrexate (mtx). oral mucositis occurs in about 20% of patients receiving methotrexate identifying risk factors leading to this side effects would be valuable to develop preventive interventions and improve quality of life for these patients . previous studies revealed a relationship between vitamin d deficiency and chemotherapy-induced oral mucositis in cancer patients. this hormone is important in many physiological processes in the body as bone mineralization and immune regulations. the main sourses of vitamin d is production in the skin through sunlight exposure, diet and vitamin d supplements . previous literature showed that receptors for vitamin d expressed in the mucosa and so there is a relationship between vitamin d deficiency and increase inflammation and impairment of mucosa . patients with acute lymphoblastic leukemia maybe at risk of vitamin d deficiency because of impaired vitamin intake and sunlight exposure . in this study we examin the possible role of vitamin d in relation to methotrexate induced oral mucositis in cancer patients. * peripheral blood samples from patients before starting chemotherapy course with methotrexate and 24 hr after starting the treatment for measurement level of vitamin d, samples centrifuged at the speed of 2000 - 3000 rpm for 20 min , then analyzed using elisa. * blood samples after treatment also used to determine serum level of methotrexate which may lead to toxic adverse effect as oral mucositis , samples centrifuged at speed of 2000 - 3000 rpm for 10 min and analyzed using viva-e equipment. * all serum samples were stored at -80 °c and analyzed collectively

Eligibility criteria:
inclusion criteria: * patients with acute lymphocytic leukemia in south egypt cancer institute * patients recieving methotrexate in protocol of treatment * both sex included exclusion criteria: * patients with other types of tumors * patients refuse to join the research * patients with comorbid hepatic or renal impairment
pentoxifylline (trental) as a modulator of tumor necrosis factor and of hiv replication in patients with aids

Conditions: HIV Infections

Summary: to determine whether pentoxifylline lowers tumor necrosis factor (tnf) levels in aids patients. pentoxifylline decreases tumor necrosis factor (tnf), and therefore should decrease such tnf-intensified events as cachexia, enhanced hiv expression, and inhibition of zidovudine (azt) activity.

pentoxifylline decreases tumor necrosis factor (tnf), and therefore should decrease such tnf-intensified events as cachexia, enhanced hiv expression, and inhibition of zidovudine (azt) activity. twenty-seven aids patients with elevated tnf and less than 300 cd4 cells are given pentoxifylline 3 times a day for 8 weeks. if no significant changes are seen in virologic, immunologic, or related measures, 27 additional patients are given a higher dose of pentoxifylline 3 times a day for eight weeks.

Eligibility criteria:
inclusion criteria concurrent medication: required: * zidovudine (azt), didanosine (ddi), dideoxycytidine (ddc), or a combination thereof, at current dosage for the 8 weeks of study treatment. * prophylaxis (e.g., aerosolized pentamidine, trimethoprim / sulfamethoxazole (tmp / smx), dapsone for pneumocystis carinii pneumonia (pcp) if cd4 cell count is \< 200 cells/mm3 allowed: * concurrent maintenance therapy for opportunistic infections. prior medication: required: * zidovudine (azt), didanosine (ddi), dideoxycytidine (ddc), or a combination thereof, for at least 2 months. patients must have the following: * diagnosis of aids. * documented hiv seropositivity. * ability to give informed consent and willingness to comply with visit schedule and all procedures. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * lymphoma or visceral kaposi's sarcoma. * active peptic ulcer or bleeding disorder. * hemophilia. known intolerance to pentoxifylline, theophylline, or caffeine. concurrent medication: excluded: * warfarin and heparin. * biological response modifiers (e.g., erythropoietin, interferon, g-csf, gm-csf). cytotoxic chemotherapy. * megestrol acetate. corticosteroids. concurrent treatment: excluded: * radiation therapy. blood products or transfusions. patients with the following are excluded: * presence of an active opportunistic infection. * major surgery within 30 days of study treatment. prior medication: excluded: * biological response modifiers (including interferon, interleukin), corticosteroids, or megestrol acetate within 14 days of first (screening) tnf level. * erythropoietin dependency or within 30 days of study treatment. prior treatment: excluded: * transfusion or blood product dependency or use within 30 days of study treatment.

Keywords: pentoxifylline virus replication tumor necrosis factor drug evaluation acquired immunodeficiency syndrome cachexia drug synergism
sternomental displacement test for predicting difficult airway in obese patients

Conditions: Difficult Airway Intubation

Summary: difficulties airway significantly contribute to the morbidity and mortality associated with anesthesia. identifying situations and patients at risk for airway management problems is the key to optimal care and has been the focus of numerous publications. although controversial, body mass index (bmi) is considered as associated with difficult intubation in both and operating theaters. a modified measurement of smd is obtained with the head in neutral position (smd neutral), then the difference between smd extension and smd neutral was calculated and it was referred to as sternomental displacement (smdd). smdd was proved to be a good objective predictor for difficult laryngoscopy in adult patients, and its predictive ability was increased when combined with other tests as neck circumference (nc). to the best of our knowledge, the validity of the smdd test was not previously assessed in obese patients.


Eligibility criteria:
inclusion criteria: * patients of either sex, aged between 18-60 years old, asa physical status ii \& iii with bmi \> 30 kg/m2 undergoing elective surgical procedures under general anesthesia using endotracheal intubation by conventional laryngoscopy. exclusion criteria: * neuromuscular disorders, craniofacial abnormalities, abnormal dentition, lesions or scares in head and neck limiting the neck mobility, uncooperative, who needed awake intubation and patients who underwent emergency operations
genotype-guided treatment in dlbcl

Conditions: Diffuse Large B Cell Lymphoma

Summary: a multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (r-chop-x) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (r-chop) in patients with diffuse large b-cell lymphoma


Eligibility criteria:
inclusion criteria: * histologically-confirmed diffuse large b-cell lymphoma (without central nervous system involvement) * availability of archival or freshly collected tumor tissue before study enrolment * international prognostic index (ipi) score of 2-5 or 1 with bulky disease * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * life expectancy greater than or equal to (\>/=) 6 months * the patient or his or her legal representative must provide written informed consent prior to any special examination or procedure for the research exclusion criteria: * previous chemotherapy. * previous stem cell transplantation. * history of malignancies except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix * uncontrolled cardio- and cerebro-vascular disease, blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases * patients with central nervous system (cns) lymphoma * primary mediastinal large b-cell lymphoma * left ventricular ejection fraction\<50% * laboratory measures meet the following criteria at screening (unless caused by lymphoma): 1. neutrophils\<1.5×10\^9/l 2. platelets\<75×10\^9/l (platelets\<50×10\^9/l in case of bone marrow involvement) 3. alt or ast is 2 times higher than the upper limits of normal (uln), akp and bilirubin are 1.5 times higher than the uln. 4. creatinine is 1.5 times higher than the uln. * hiv-infected patients * positive test results for chronic hepatitis b and hepatitis c infection * patients with psychiatric disorders or patients who are known or suspected to be unable to fully comply with the study protocol * pregnant or lactation * require treatment with strong/moderate cyp3a inhibitors or inducers. * inability to swallow capsules or presence of diseases that significantly affect gastrointestinal function, such as malabsorption syndrome, post-bariatric surgery, inflammatory bowel disease and complete or incomplete intestinal obstruction * other medical conditions determined by the researchers that may affect the study
contoura with phorcides compared to wavefront optimized lasik

Conditions: Myopia; Astigmatism

Summary: comparing post-operative visual acuity and patient reported satisfaction between contoura with phorcides and wavelight wavefront optimized.


Eligibility criteria:
inclusion criteria: * patients at least age 21 years of age undergoing lasik eye surgery * willing and able to comprehend informed consent and complete 1 month post-op visit * potential postoperative bcdva of 20/20 or better in each eye based on investigator's medical opinion * candidates for contoura with phorcides (myopic, astigmatism \<3.0d) * both eyes targeted for plano * pre-operative total corneal pachymetry 490um or above * stable refractive error \<0.50d change in preceding year * good general and ocular health * pre-operative exam completed within three months of surgery * scl discontinued 3 days prior to pre-op exam and the procedure * pachymetry above 490 with residual greater than 270um * candidates who, as determined by the investigator, can safely undergo lasik exclusion criteria: * patients under 21 years of age * concomitant ocular condition which would limit the bcva at the discretion of the surgeon * patients with usual relative and absolute contraindications for lasik surgery (patients with severe dry eye, recurrent corneal erosion, uncontrolled glaucoma, collagen vascular disorders, keratoconus or signs of keratoconus, uncontrolled diabetes, herpes) * pachymetry below 490 * autoimmune or immunodeficiency diseases * pregnant or nursing women * patients with signs of inability to understand consent for study and procedure planned * patients with history of previous ocular surgery * patients with strabismus or amblyopia * patients that have a bcdva of 20/25 or worse in either eye

Keywords: visual acuity refractive outcome lasik contrast sensitivity wavefront optimized topography-guided
clinical pharmacology of fyu-981 (subjects with renal insufficiency)

Conditions: Renal Insufficiency; Healthy

Summary: the purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety after single oral administration of fyu-981 to subjects with renal insufficiency and with normal renal function.


Eligibility criteria:
inclusion criteria: * japanese adult subjects * body mass index: \>=18.5 and \<30.0 exclusion criteria: * subjects with any disease or any history of diseases that might be unsuitable for participation in the clinical study